glp 1 concentration GLP-1 (A), GIP (B), and glucagon (C) profiles before GLP-1 receptor agonists in the

Physicians on Sermo share experiences with GLP-1 weight loss drugs and risks

The evidence suggests that traditional management strategies focusing on either condition in isolation fall short of addressing the intertwined nature of diabetes and depression

GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health

GLP-1 receptor agonists cost between $150 and $1,300+ per month depending on formulation, supply, and sourcing

From study baseline to the end of follow-up, GLP-1RAs treatment resulted in statistically significant decreases in weight (MD=-2.32 kg, 95% CI: -4.21 to -0.43) and BMI (MD=-0.82 kg/m2, 95% CI: -1.47 to -0.17)